Who
Kevin Robert Lind
Director
Company insider
Files Form 4 as: Director, Avalo Therapeutics; Chief Executive Officer, Apnimed; President and CEO, Longboard Pharmaceuticals; Executive VP and CFO, Arena Pharmaceuticals.
In numbers
- Trades disclosed
- 57
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $248K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 15 Jun 2016
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $17K1,352 at $12.29 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —74,128 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,128 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,186,278 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —74,128 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,128 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,186,278 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,186,278 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —108,916 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —108,916 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,186,278 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code D | —108,916 at $0.00 | filing |
| 3 Aug 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —108,916 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —108,916 at $0.00 | filing |
| 30 Jul 2026filed 3 Aug 2026 | APMD Apnimedoption or derivative · Biotechnology | SEC FORM 4 Code A | —108,916 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $17K1,105 at $15.04 | filing |
| 30 Jun 2026filed 2 Jul 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $17K1,105 at $15.04 | filing |
| 2 Jun 2026filed 4 Jun 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 2 Jun 2026filed 4 Jun 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 31 Mar 2026filed 1 Apr 2026 | AVTX Avalo Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $17K1,370 at $12.13 | filing |
News
No headline names them, or the companies they trade most, lately.